World Crypto Global
- Written by: (Investorideas.com newswire, breaking stock market
- Thu, 12 May 2022
- United States
Vancouver, British Columbia - May 12, 2022 (Newsfile Corp.) (Investorideas.com Newswire) NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF), a clinical stage biotech company dedicated to developing a first-in-class neuroreparative drug to treat nervous system damage, today announced it has received approval from the Safety Review Committee to advance to the third and highest dose cohort in the multiple ascending dose portion of its Phase 1 clinical trial of the Company's proprietary lead compound, NVG-291.
